Potencies of oral contraceptives.
Oral contraceptives are combinations of estrogens and progestogens or, in the case of the mini-pills, progestogens alone. With specific test procedures in laboratory animals or human subjects, it is possible to assign potency evaluations to the components relative to the progestational, estrogenic, or antiestrogenic activities of the progestogen or to the estrogenic potencies of the estrogenic component. It might even be possible to quantify the synergistic effects of the estrogen on the progestational agent. Unfortunately, however, it is impossible now to amalgamate such assay results into single estimates of the potencies of the combinations (either the combination products per se or the combination tablets of sequential products). For example, an over-all estrogenic potency of a combination preparation would involve the integration of contributions form the estrogen itself plus the estrogenic products of metabolism of the progestogen minus the antagonistic effect of the progestational agent, if any. These factors cannot now be quantified independently, much less merged into a single figure of clinical significance. Further, even if it were possible to produce such an estimate, it is unlikely that the evaluation would be meaningful in relation to any putative side effect or adverse reaction, i.e., the alleged thrombogenic effects of oral contraceptives cannot currently be related directly to any measure of potency that will allow prediction of these clinical conditions from laboratory models. Any evaluation of the potential of a given contraceptive to produce a specific side effect will depend upon data generated with specific regard to that adverse reaction and the individual product in question.
D003276:Contraceptives, Oral / Q000494:pharmacology*; D003277:Contraceptives, Oral, Combined / Q000494:pharmacology; D003279:Contraceptives, Oral, Sequential / Q000494:pharmacology; D003280:Contraceptives, Oral, Synthetic / Q000009:adverse effects / Q000494:pharmacology; D004347:Drug Interactions; D045166:Estradiol Congeners / Q000009:adverse effects / Q000494:pharmacology; D004967:Estrogens / Q000494:pharmacology; D005260:Female; D006801:Humans; D011247:Pregnancy; D045167:Progesterone Congeners / Q000009:adverse effects / Q000494:pharmacology; D011372:Progestins / Q000494:pharmacology / Q000502:physiology; D013923:Thromboembolism / Q000139:chemically induced
D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D003279:Contraceptives, Oral, Sequential; D003280:Contraceptives, Oral, Synthetic; D045166:Estradiol Congeners; D004967:Estrogens; D045167:Progesterone Congeners; D011372:Progestins